Humacyte Faces Class Action Lawsuit Over Alleged Misleading Statements to Investors

### Humacyte Faces Legal Challenges Over Allegations of Misleading Statements

Humacyte, Inc., a biotechnology firm specializing in the development and manufacturing of off-the-shelf, implantable bioengineered human tissues, finds itself embroiled in a class action lawsuit initiated by several law firms on behalf of its shareholders. The allegations stem from claims that Humacyte misled investors regarding its operational compliance, particularly related to its manufacturing facility in Durham, North Carolina. The lawsuit encompasses a class period from May 10, 2024, to October 17, 2024, during which time Humacyte reportedly made false and misleading statements about its adherence to good manufacturing practices and the quality assurance processes necessary for regulatory compliance.

The core of the allegations involves Humacyte's failure to maintain proper quality control measures, including microbial testing, which is critical for ensuring the safety and efficacy of its products. These alleged deficiencies prompted the Food and Drug Administration (FDA) to extend its review of Humacyte's Biologics License Application (BLA) for its Acellular Tissue Engineered Vessel (ATEV), a product aimed at treating vascular trauma. The lawsuit claims that the company’s executives did not adequately disclose these compliance issues, which ultimately led to delays in the FDA's approval process. As the revelations surfaced, Humacyte's optimistic public statements were deemed materially misleading, contributing to significant investor losses.

Following critical disclosures, including a Form 483 issued by the FDA that highlighted multiple violations at the Durham facility, Humacyte's stock price experienced notable declines—dropping 16.4% in August and a similar percentage in October 2024. Shareholders are now encouraged to participate in the class action, with a deadline for filing lead plaintiff motions set for January 17, 2025. Law firms involved in the case operate on a contingency fee basis, ensuring that investors incur no upfront costs unless the case results in a recovery.

In addition to the ongoing litigation, Humacyte's challenges underscore broader concerns in the biotechnology sector regarding regulatory compliance and transparency. The case highlights how operational shortcomings can significantly impact investor confidence and market performance, particularly in an industry where the stakes surrounding product safety and efficacy are exceptionally high. As Humacyte navigates this legal landscape, the outcome could have lasting implications for its operational practices and investor relations moving forward.

Shareholders affected by the alleged misleading statements can seek representation from various law firms specializing in securities litigation, which are actively pursuing claims on behalf of investors. With a history of securing substantial recoveries for harmed shareholders, these firms aim to hold Humacyte accountable while advocating for improved corporate governance in the biotechnology space.